Results 121 to 130 of about 163,448 (315)
Association between plasma cyclic guanosine monophosphate levels and hemodynamic instability during liver transplantation [PDF]
, 2012 Dmitri Bezinover +7 more
openalex +1 more source
Bemnifosbuvir: An HCV NS5B Inhibitor With Multiple Modes of Action
Clinical Pharmacology &Therapeutics, EarlyView.Bemnifosbuvir (BEM) is a potent, pan‐genotypic inhibitor targeting the hepatitis C virus (HCV) NS5B polymerase. Its antiviral activity was evaluated in an ascending dose phase I clinical trial involving 30 patients treated once a day for 7 days. After treatment initiation, plasma HCV RNA declined in a biphasic manner with a mean reduction of 2.3 log10 ...
Carolin Zitzmann +4 more
wiley +1 more source
Interactions between a lymphoma membrane-associated guanosine 5'-triphosphate-binding protein and the cytoskeleton during receptor patching and capping. [PDF]
, 1990 Lilly Bourguignon +2 more
openalex +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia +2 more
wiley +1 more source
The role of DNA and RNA guanosine oxidation in cardiovascular diseases
Pharmacological ResearchCardiovascular diseases (CVD) persist as a prominent cause of mortality worldwide, with oxidative stress constituting a pivotal contributory element. The oxidative modification of guanosine, specifically 8-oxoguanine, has emerged as a crucial biomarker ...
Yiping Li, Xiaolong Wang
doaj +1 more source
Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy
ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo +7 more
wiley +1 more source
Guanosine monophosphate synthetase from Escherichia coli B-96. Inhibition by nucleosides.
, 1975 T Spector, LM Beacham
openalex +1 more source
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source
BMC MicrobiologyThe overproduction of uric acid, driven by its key precursors (inosine and guanosine), leads to hyperuricemia, a metabolic disorder associated with severe complications such as gout and renal dysfunction.
Xiaoyu Cao +3 more
doaj +1 more source